000 | 01370 a2200397 4500 | ||
---|---|---|---|
005 | 20250516024929.0 | ||
264 | 0 | _c20110804 | |
008 | 201108s 0 0 jpn d | ||
022 | _a0917-5857 | ||
024 | 7 |
_aCliCa1103429438 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aTaguchi, Tetsuya | |
245 | 0 | 0 |
_a[Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer]. _h[electronic resource] |
260 |
_bClinical calcium _cMar 2011 |
||
300 |
_a429-38 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Review | ||
650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
650 | 0 | 4 |
_aBone Density Conservation Agents _xpharmacology |
650 | 0 | 4 |
_aBone Neoplasms _xpathology |
650 | 0 | 4 |
_aBreast Neoplasms _xpathology |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 | _aDenosumab |
650 | 0 | 4 |
_aDiphosphonates _xpharmacology |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImidazoles |
650 | 0 | 4 | _aMolecular Targeted Therapy |
650 | 0 | 4 |
_aOsteoclasts _xdrug effects |
650 | 0 | 4 | _aPamidronate |
650 | 0 | 4 |
_aRANK Ligand _xphysiology |
650 | 0 | 4 |
_aStrontium _xtherapeutic use |
650 | 0 | 4 | _aZoledronic Acid |
773 | 0 |
_tClinical calcium _gvol. 21 _gno. 3 _gp. 429-38 |
|
856 | 4 | 0 |
_uhttps://doi.org/CliCa1103429438 _zAvailable from publisher's website |
999 |
_c20632993 _d20632993 |